#ESMO22: Mirati vs Amgen: Scrappy KRAS G12C contender outperforms its giant rival in colorectal cancer

PARIS — This weekend at ESMO, the KRAS battle between Amgen and its pesky biotech rivals at Mirati will continue with new slices of combo data for advanced cases of colorectal cancer. And once again, Mirati will get in with a solid punch.

Chuck Baum

Click to view original post